Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 15/20 | 0.63 |
| ▸ | ATP4B | P51164 | 15/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.63 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | FASN | P49327 | 1/20 | 0.63 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.63 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.63 |
| ▸ | ATP1A1 | P05023 | 9/20 | 0.54 |
| ▸ | ATP1B1 | P05026 | 9/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantoprazole SCHEMBL29463615 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL22198 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL29530572 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL30777582 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL29466 | 1.00 | ATP4A (0.63) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL3179782 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL289961 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL1994486 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL1716779 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| Pantoprazole SCHEMBL29001005 | 0.99 | ATP4A (0.62) | ATP4AATP4BCYP2C9CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398908-A2 | TREATMENT OF NEUROLOGICAL DISORDERS | GMP Biotechnology Limited (CN) | 2024-07-17 | — | — | EP | claimed |
| US-20240216359-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | GMP BIOTECHNOLOGY LTD (CN) | 2024-07-04 | — | — | US | claimed |
| US-20240093198-A1 | TGF-BETA THERAPEUTICS FOR AGE DISEASE | GMP BIOTECHNOLOGY LTD (CN) | 2024-03-21 | — | — | US | claimed |
| WO-2023039345-A2 | TREATMENT OF NEUROLOGICAL DISORDERS | ONCOTELIC, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| EP-2056884-B1 | METHOD AND COMPOSITION TO EVALUATE CYTOCHROME P450 2C19 ISOENZYME ACTIVITY USING A BREATH TEST | CAMBRIDGE ISOTOPE LAB INC (US) | 2016-11-30 | — | — | EP | claimed |
| CN-105380919-A | Pantoprazole sodium enteric-coated tablet and preparation method thereof | SHIMAO TIANJIE PHARMACEUTICALS (JIANGSU) CO LTD | 2016-03-09 | — | — | CN | claimed |
| CN-105310999-A | Pantoprazole sodium enteric capsule for treating peptic ulcer | LI ZHENGMEI | 2016-02-10 | — | — | CN | claimed |
| CN-105193745-A | Pantoprazole sodium freeze-drying medicine composition for injection and preparation method thereof | KAMP PHARMACEUTICALS CO LTD | 2015-12-30 | — | — | CN | claimed |
| US-20140154190-A1 | Skin Lightening Compositions | ELC MANAGEMENT, LLC (US) | 2014-06-05 | — | — | US | claimed |
| US-7683177-B2 | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2010-03-23 | — | — | US | claimed |
| CN-1689568-A | Pharmaceutical composition containing cyclodextrin derivatives and proton pump inhibitor of parietal cell | YIN XIAOFENG (CN) | 2005-11-02 | — | — | CN | claimed |
| EP-4673144-A1 | CANCER THERAPY WITH TGF-BETA-2 AND IRINOTECAN AGENTS | GMP Biotechnology Limited (HK) | 2026-01-07 | — | — | EP | disclosed |
| US-20250382619-A1 | CANCER THERAPY WITH TGF-BETA-2 AND IRINOTECAN AGENTS | GMP BIOTECHNOLOGY LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250332340-A1 | COMPOSITIONS AND METHODS FOR CNS DISEASES | GMP BIOTECHNOLOGY LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| EP-4615467-A2 | COMPOSITIONS AND METHODS FOR CNS DISEASES | GMP Biotechnology Limited (CN) | 2025-09-17 | — | — | EP | disclosed |
| EP-0944617-B1 | CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND THEIR PRODUCTION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| CN-1334731-A | Novel pharmaceutical formulations | ASTRAZENECA AB (SE) | 2002-02-06 | — | — | CN | disclosed |
| US-6002011-A | Crystals of benzimidazole derivatives and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-14 | — | — | US | disclosed |
| EP-0944617-A1 | CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND THEIR PRODUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998021201-A1 | CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND THEIR PRODUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382619-A1 | CANCER THERAPY WITH TGF-BETA-2 AND IRINOTECAN AGENTS | FOLR2, TGFB2, TGFBR2 | ATP4A 2353/4885ATP4B 896/4885CYP2C9 3107/4885 |
| US-20140154190-A1 | Skin Lightening Compositions | TYR, MC1R, AHR | ATP4A 3964/4885ATP4B 4059/4885CYP2C9 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.